Cryopyrin-associated periodic syndrome natural history, complications and prognosis
Cryopyrin-associated periodic syndrome Microchapters |
Differentiating Cryopyrin-associated periodic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cryopyrin-associated periodic syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
FDA on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
CDC on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
Cryopyrin-associated periodic syndrome natural history, complications and prognosis in the news |
Blogs on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of Neonatal-onset multisystem inflammatory disease (NOMID) include:[1][2]
- Sensorineural hearing loss
- Hydrocephalus and increased intracranial pressure
- Optic nerve atrophy and progressive vision loss
- Cognitive delay
- Deforming arthropathy (30-40% 0f the cases)
- Renal amyloidosis
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Sibley, Cailin H.; Plass, Nikki; Snow, Joseph; Wiggs, Edythe A.; Brewer, Carmen C.; King, Kelly A.; Zalewski, Christopher; Kim, H. Jeffrey; Bishop, Rachel; Hill, Suvimol; Paul, Scott M.; Kicker, Patrick; Phillips, Zachary; Dolan, Joseph G.; Widemann, Brigitte; Jayaprakash, Nalini; Pucino, Frank; Stone, Deborah L.; Chapelle, Dawn; Snyder, Christopher; Butman, John A.; Wesley, Robert; Goldbach-Mansky, Raphaela (2012). "Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes". Arthritis & Rheumatism. 64 (7): 2375–2386. doi:10.1002/art.34409. ISSN 0004-3591.
- ↑ Hill, Suvimol Chirathivat; Namde, Madjimbaye; Dwyer, Andrew; Poznanski, Andrew; Canna, Scott; Goldbach-Mansky, Raphaela (2006). "Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA)". Pediatric Radiology. 37 (2): 145–152. doi:10.1007/s00247-006-0358-0. ISSN 0301-0449.